

Approval at the Sugarloaf Mountain

Bioabsorbable MAGNEZIX® CBS approved for medical use in Brazil

Hanover, 31 May 2021 – Syntellix AG has reached another important milestone in the context of its global footprint strategy: The Brazilian health authority ANVISA has approved the product family MAGNEZIX® CBS with 2.7- and 3.5-millimetre diameter. The cortical screws developed, and distributed by Syntellix can now be used for the surgical treatment of small and large bone fragments in the world's fifth largest country by area and sixth most populous country according to World Bank data. Within the human body, the magnesium-based implants transform into bone mass over time, eliminating the need for a second material removal surgery, which is often required with traditional titanium or steel implants.

Brazil is already the 68th country for which the patent-protected MAGNEZIX® implants, which combine bioabsorbability and stability, have been approved for use in orthopaedics and trauma surgery. After Mexico, the most populous Central American country, was opened up in January 2019, the most populous South American country, Brazil, with more than 200 million inhabitants, is now following. As Chile, Ecuador, Panama and Peru have already granted product approvals for MAGNEZIX® implants, the majority of Latin America is now on the Syntellix world map. With a view to Brazilian patients and the upcoming market entry in Brazil, Syntellix CEO Prof. Dr. Utz Claassen emphasises: "MAGNEZIX®, with its numerous advantages over conventional technologies, should become available to the widest possible range of medical institutions throughout the country".

Avoiding second operations for implant removal reduces medical risks in many respects, saves costs and protects the environment. This way, physicians who already use the highly innovative MAGNEZIX® technology make a significant contribution to patient safety and resource conservation. Through the achieved approval, the MAGNEZIX® ecosystem will continue to grow, also on the American continent.

302 words / 2,060 characters (including spaces)

About Syntellix:

Syntellix AG, a global pioneer in biomedical technology, materials & life science that has already received numerous national and international awards, is the worldwide market leader in the field of bioabsorbable metallic implants in orthopaedics and trauma surgery. Around 40 medical scientific publications in peer-reviewed journals have proven safety, efficacy, reliability and advantageousness of MAGNEZIX® implants.

Syntellix AG
Aegidientorplatz 2a
30159 Hannover
Germany

T +49 511 270 413 50
F +49 511 270 413 79

info@syntellix.com
www.syntellix.com

Executive Board
Prof. Dr. rer. pol.
Utz Claassen
Chairman of the Executive
Board/CEO & Chief
Disruption Officer

Dr. rer. pol. oec.
Amir S. Ghoreishi
CFO

Prof. Dr. med.
Martin Kirschner
Chief Medical Officer

**Chair of the Supervisory
Board**
Annette Claassen

Registered Office
Hannover
Amtsgericht Hannover
HRB 202618

For further information:
Michael Blum
press@syntellix.com

Disclaimer:
This press release is a translation and has been issued for information purposes only. Should there be any discrepancy between this translation and the original German text, the latter shall be the legally binding version.